ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.

Katrina S PedersenNathan R FosterMichael James OvermanPatrick M BolandSunnie S KimKathryn A ArrambideBrandy L JaszewskiTanios Bekaii-SaabRondell P Graham Jack WelchRichard H WilsonRobert R McWilliams

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

In the largest study of SBA to date, pembrolizumab did not induce the hypothesized response rate; however, we did identify responses in key biomarker-selected cohorts.

Keyphrases

phase ii study
small bowel
locally advanced
advanced non small cell lung cancer
open label
squamous cell carcinoma
clinical trial
cross sectional
radiation therapy